Pancreatic Neoplasms

"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Descriptor ID	D010190
MeSH Number(s)	C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
Concept/Terms	Pancreatic Neoplasms Pancreatic Neoplasms Neoplasm, Pancreatic Pancreatic Neoplasm Pancreas Neoplasms Neoplasm, Pancreas Neoplasms, Pancreas Pancreas Neoplasm Neoplasms, Pancreatic Cancer of Pancreas Cancer of Pancreas Pancreas Cancers Pancreas Cancer Cancer, Pancreas Cancers, Pancreas Pancreatic Cancer Cancer, Pancreatic Cancers, Pancreatic Pancreatic Cancers Cancer of the Pancreas

Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Digestive System Neoplasms [C04.588.274]
Pancreatic Neoplasms [C04.588.274.761]
Endocrine Gland Neoplasms [C04.588.322]
Pancreatic Neoplasms [C04.588.322.475]
Digestive System Diseases [C06]
Digestive System Neoplasms [C06.301]
Pancreatic Neoplasms [C06.301.761]
Pancreatic Diseases [C06.689]
Pancreatic Neoplasms [C06.689.667]
Endocrine System Diseases [C19]
Endocrine Gland Neoplasms [C19.344]
Pancreatic Neoplasms [C19.344.421]

Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 201 publications over 27 distinct years, with a maximum of 22 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	3	0	3
1999	1	1	2
2000	3	0	3
2001	1	0	1
2002	2	0	2
2003	4	0	4
2004	4	1	5
2005	3	1	4
2006	3	0	3
2007	8	0	8
2008	5	1	6
2009	8	1	9
2010	12	0	12
2011	2	0	2
2012	13	1	14
2013	9	1	10
2014	7	0	7
2015	12	1	13
2016	22	0	22
2017	16	2	18
2018	9	0	9
2019	13	0	13
2020	10	2	12
2021	9	0	9
2022	4	0	4
2023	5	0	5

Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.

Papageorge MV, de Geus SWL, Woods AP, Ng SC, McAneny D, Tseng JF, Kenzik KM, Sachs TE. The Evaluation of Gallstone Disease in the Year Before Pancreatic Cancer Diagnosis. J Surg Res. 2023 11; 291:282-288.

View in: PubMed
Perez K, Chiarella AM, Cleary JM, Horick N, Weekes C, Abrams T, Blaszkowsky L, Enzinger P, Giannakis M, Goyal L, Meyerhardt JA, Rubinson D, Yurgelun MB, Goessling W, Giantonio BJ, Brais L, Germon V, Stonely D, Raghavan S, Bakir B, Das K, Pitarresi JR, Aguirre AJ, Needle M, Rustgi AK, Wolpin BM. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist. 2023 05 08; 28(5):425-432.

View in: PubMed
Chibaya L, Murphy KC, DeMarco KD, Gopalan S, Liu H, Parikh CN, Lopez-Diaz Y, Faulkner M, Li J, Morris JP, Ho YJ, Chana SK, Simon J, Luan W, Kulick A, de Stanchina E, Simin K, Zhu LJ, Fazzio TG, Lowe SW, Ruscetti M. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat Cancer. 2023 06; 4(6):872-892.

View in: PubMed
McBrearty N, Cho C, Chen J, Zahedi F, Peck AR, Radaelli E, Assenmacher CA, Pavlak C, Devine A, Yu P, Lu Z, Zhang H, Li J, Pitarresi JR, Astsaturov I, Cukierman E, Rustgi AK, Stanger BZ, Rui H, Fuchs SY. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Mol Cancer Res. 2023 03 01; 21(3):228-239.

View in: PubMed
Sayin S, Rosener B, Li CG, Ho B, Ponomarova O, Ward DV, Walhout AJM, Mitchell A. Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells. Elife. 2023 02 03; 12.

View in: PubMed
Lefler JE, MarElia-Bennett CB, Thies KA, Hildreth BE, Sharma SM, Pitarresi JR, Han L, Everett C, Koivisto C, Cuitino MC, Timmers CD, O'Quinn E, Parrish M, Romeo MJ, Linke AJ, Hobbs GA, Leone G, Guttridge DC, Zimmers TA, Lesinski GB, Ostrowski MC. STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Life Sci Alliance. 2022 11; 5(11).

View in: PubMed
Marya NB, Levy MJ. EUS-guided intratumoral therapies: more time on the treadmill. Gastrointest Endosc. 2022 06; 95(6):1264-1267.

View in: PubMed
Keith SW, Maio V, Arafat HA, Alcusky M, Karagiannis T, Rabinowitz C, Lavu H, Louis DZ. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. BMC Cancer. 2022 Feb 07; 22(1):150.

View in: PubMed
Papageorge MV, de Geus SWL, Woods AP, Ng SC, McAneny D, Tseng JF, Kenzik KM, Sachs TE. The Effect of Hospital Versus Surgeon Volume on Short-Term Patient Outcomes After Pancreaticoduodenectomy: a SEER-Medicare Analysis. Ann Surg Oncol. 2022 Apr; 29(4):2444-2451.

View in: PubMed
Papageorge MV, de Geus SWL, Woods AP, Ng SC, McAneny D, Tseng JF, Kenzik KM, Sachs TE. The impact of upper gastrointestinal surgical volume on short term pancreaticoduodenectomy outcomes for pancreatic adenocarcinoma in the SEER-Medicare population. HPB (Oxford). 2022 06; 24(6):868-874.

View in: PubMed

People

Explore

Similar Concepts

Top Journals